Biodesix® Announces Additional Data in Phase III Lung Cancer Diagnostic Study
PROSE confirms VeriStrat can predict differential treatment outcomes in 2nd line advanced NCLSC patients.
×
254 Results
PROSE confirms VeriStrat can predict differential treatment outcomes in 2nd line advanced NCLSC patients.
Biodesix closed on $8.8 million in a follow-on sale of its Series D preferred shares.
Data confirms that the blood-based protein diagnostic is predictive of differential treatment outcomes between two types of therapies for 2nd line NSCLC.
Paul Beresford, Ph.D., will present at the 2013 World CDx Summit taking place in Boston, November 12-15, 2013; Benefits of proteomics in test discovery.
Biodesix presents data on VeriStrat biomarker study at ASCO 2013
Bioesix's Veristrat test gains coverage from Medicare. More than 49 million Medicare enrollees in the U.S. will now be able to benefit from VeriStrat.
CE Mark clears Biodesix to make VeriStrat results available to physicians in the European Union and other countries recognizing the CE Mark.
Biodesix announced today that the company closed an $8.3 million Series E preferred equity financing. Existing shareholders provided all of the capital.
Biodesix has closed a structured debt financing with Capital Royalty Partners L.P. The transaction provides Biodesix®with up to $20 million of capital.
Biodesix increases the size of its recent offering of series E preferred shares in a follow-on sale; Total series E preferred shares of $14.4 million.